Gland Pharma

Name

Gland Pharma

Legal name

Gland Pharma Limited

Website

https://glandpharma.com

Company type

Public

Founded year

1978

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Generic Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Generic injectable pharmaceuticals
• Sterile injectables manufacturing
• Contract development manufacturing
• Active pharmaceutical ingredients
• Ophthalmic injectable products

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Generic Injectables Manufacturing and Sales: Manufacture and sale of generic injectable pharmaceuticals including sterile injectables, oncology drugs, and ophthalmic products to global pharmaceutical companies and healthcare providers.
2. Contract Development and Manufacturing (CDMO): CDMO services for other pharmaceutical companies, offering contract manufacturing, technology transfer, and development services. The CDMO segment contributed nearly half of consolidated revenue and grew 28% in FY26.
3. API (Active Pharmaceutical Ingredient) Manufacturing: In-house manufacturing of APIs providing backward integration and supply chain control, supporting 32 ANDAs with in-house API capabilities.
4. Technology Transfer Services: Technology transfer projects where customers transfer technology to Gland Pharma for manufacturing, involving technical gap analysis, analytical method transfers, and validation.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Gland Pharma manufactures and supplies generic injectable pharmaceuticals including sterile injectables, oncology injectables, and ophthalmic products across 60+ countries. The company operates four cGMP-compliant formulation facilities and four API facilities in India, supported by two R&D divisions in Hyderabad with nearly 300 scientists. It also offers Contract Development and Manufacturing Organization (CDMO) services encompassing formulation development, analytical method development, API process development, and technology transfer, with European operations delivered through its acquired subsidiary Cenexi Group.

Product overview

Gland Pharma is a global injectable-focused pharmaceutical company operating primarily under a B2B (business-to-business) model. The company offers a vertically integrated portfolio combining Contract Development and Manufacturing Organization (CDMO) services with proprietary generic injectable products. The core offerings include sterile injectables manufacturing (solutions, lyophilized products, suspensions, pre-filled syringes), API manufacturing for backward integration, oncology injectables, and ophthalmic products. Their CDMO services encompass formulation development, analytical method development, API process development, and technology transfer capabilities. The company operates 4 formulation facilities and 4 API facilities in India, with European operations through acquired subsidiary Cenexi Group. They focus on complex injectables, First-to-File products, and 505(b)(2) filings with regulatory approvals from USFDA, MHRA, ANVISA, TGA, and other agencies.

Differentiator

Problem solved

Functional benefit

Products and services

• Contract Development and Manufacturing Organization (CDMO) Services Comprehensive CDMO services for sterile injectables, including formulation development, analytical method development, API process development, stability studies, technology transfer, and contract manufacturing for global pharmaceutical partners.
• Sterile Injectables Manufacturing Manufacturing of sterile injectable products including solutions, suspensions, lyophilized products, pre-filled syringes, vials, ampoules, bags, and dry powder injections using aseptic filling or terminal sterilization.
• Generic Injectables Portfolio Broad portfolio of generic injectable medications including complex generic injectables, NCE-1s, First-to-File products, and 505(b)(2) filings for regulated markets.
• Active Pharmaceutical Ingredients (API) Manufacturing In-house API manufacturing across four facilities enabling backward integration and supply chain control, particularly for difficult-to-source APIs including low molecular weight heparins, steroids, and oncology drugs.
• Oncology Injectables Specialized oncology injectable manufacturing including products for multiple myeloma treatment and solid tumor applications, produced at a dedicated oncology facility.
• Ophthalmic Products Ophthalmic solutions and products including prescription and OTC eye drops for conditions such as allergic conjunctivitis and eye redness relief.
• Penems Injectables Dedicated Penems facility for manufacturing of beta-lactam antibiotic injectables.
• Cenexi Group European CDMO Services

Quantifiable outcome

• Revenue grew 32% to ₹34,629 million in FY2020-21
• +6 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Apotex Inc.coreStrategic or Co-development Partner · 27 April 2026Collaboration for FDA-approved generic Infuvite Pediatric Injection. The program involved combined scientific, regulatory, and manufacturing capabilities of Apotex, Orbicular Pharmaceutical Technologies, and Gland Pharma. Apotex serves as the ANDA sponsor leading US commercialization while Gland Pharma provides manufacturing capabilities.
• Cenexi Group (Acquired)coreStrategic or Co-development Partner · 29 November 2022Gland Pharma acquired 100% stake in French CDMO Cenexi Group for up to Euro 120 million (approximately ₹1,015 crore). Cenexi specializes in sterile injectable drug development and manufacturing, expanding Gland Pharma's European presence and CDMO capabilities. The acquisition was completed in April 2023.
• Akshaya Patra FoundationminorOthersPartnership for the Free Breakfast Scheme serving nearly 9,100 children of 66 government-run schools around Gland Pharma's manufacturing facilities in Hyderabad and Visakhapatnam. Akshaya Patra prepares and supplies nutritious breakfast, with Gland Pharma providing funding support.
• LV Prasad Eye Institute (LVPEI)minorOthersHealthcare partnership for eye care. Gland Pharma contributed to LVPEI for PPE kits and medical supplies during COVID-19, and funding for setting up a dedicated 'Centre for Elderly Eye Care' at Hyderabad.
• SwayamkrushiminorOthersHyderabad-based NGO sheltering mentally challenged women. Gland Pharma contributed to construction of a Vocational Training Centre-cum-Residential Block and procurement of jute bag-making machines for vocational training.
• Nehru Zoological ParkminorOthersWildlife conservation partnership. Gland Pharma contributed ₹20 lakh to Nehru Zoological Park for adoption of animals and birds, and ₹20 lakh for kangaroo fence construction.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Sun Pharmaceutical Industries: India's largest pharmaceutical company with a meaningful specialty injectables portfolio and US generics presence. Overlaps with Gland in sterile injectables and complex generics categories across regulated markets.
• Piramal Pharma Solutions: India-based CDMO with injectable manufacturing capabilities and complex API services. Operates in the same customer segments as Gland's CDMO business and shares the Indian manufacturing and regulatory footprint.
• Cipla: Indian pharmaceutical major with growing injectables and complex generics capabilities. Has comparable US ANDA presence and is investing in sterile injectable capacity, making it a relevant peer for Gland's core business.
• Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with a significant sterile injectables portfolio and US ANDA presence. Competes directly with Gland in US generic injectables and shares the Hyderabad manufacturing base, making it the closest head-to-head comparator.
• Dr. Reddy's Laboratories: India-headquartered global pharmaceutical company with a substantial sterile injectables franchise and CDMO services. Operates in overlapping US, EU, and emerging markets with comparable complex injectable capabilities and API integration.
• Recipharm: European CDMO with sterile injectable capabilities acquired by EQT-owned consortium. Provides the most direct European CDMO comparable to Gland's newly acquired Cenexi operations in terms of service offering and customer base.
• WuXi STA: Major China-based CDMO with growing sterile injectable and small-molecule API capabilities. Competes with Gland in API and injectable CDMO, with comparable scale and complexity though different geographic risk profile.
• Catalent: Global CDMO with deep sterile injectable and parenteral drug product capabilities serving branded biopharma. Closely comparable to Gland's CDMO segment in terms of technology and customer profile, though predominantly serving innovator pharma rather than generics.

Broad incumbents

• Baxter BioPharma Solutions: Pharmaceutical contract manufacturing arm of Baxter focused on sterile injectables and parenteral products. Provides CDMO services for complex injectables, overlapping with Gland's high-potency and lyophilized product capabilities.
• Hospira (Pfizer CentreOne): Pfizer's CDMO arm and the largest US sterile injectables manufacturer. Competes broadly with Gland in the US injectable supply market and provides CDMO services for complex parenteral products, though it operates at much larger scale across a broader portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gland-pharma-limited

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Subsidiaries5 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gland Pharma